comprehensive -WSS

comprehensive

author：fashion 2025-10-02 23:31:22 - browse：29

ITeos Therapeutics offered the first look at clinical data for its experimental cancer antibody that works by blocking the novel — and very buzzworthy — protein target called TIGIT.

The tumor-shrinking activity of the company’s drug, called EOS-448, was minimal but still comparable to early study data from competing TIGIT-targeted drugs in development, including ones from Roche and Merck.

iTeos presented the EOS-448 Phase 1 study results at the annual meeting of the American Association for Cancer Research on Saturday.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Review: 'Barbie' will hit you like a shot in the heart

WSS

AbbVie dramatically boosts its spending on lobbying

Pig kidney works a record two months in donated body

Hospitals consider fixing cancer drug shortages on their own

New rules on organ donation and transplantation 'will bring chaos'

FDA panel endorses Alnylam’s heart drug — after picking it apart

FDA approves updated Covid vaccines

explore

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

How one medical school became remarkably diverse

Hyaluronic acid injections don’t help knee osteoarthritis, study finds

Moonlake's readout produced a cash windfall. Risks remain

What to know about Saharan dust affecting the US and how it can affect health

FDA approval of Sarepta Duchenne genetic therapy gives me hope

FDA approves updated Covid vaccines

Bright Health sells Medicare Advantage business to Molina

Why an extreme heat and wildfire smoke combination can be so dangerous

explore

Artificial intelligence advances fuel industry trying to preserve loved ones after death

FDA proposes changes to key medical devices approval pathway

Long Covid needs a new name — and a new frame

Artificial intelligence advances fuel industry trying to preserve loved ones after death

What to make of Biden’s latest efforts on cancer research

7 of the most gruesome medical devices in history

leisure time

hotspot

leisure time

knowledge